Please login to the form below

Not currently logged in
Email:
Password:

ALVAC-HIV

This page shows the latest ALVAC-HIV news and features for those working in and with pharma, biotech and healthcare.

HIV vaccine based on Sanofi/GSK components fails trial

HIV vaccine based on Sanofi/GSK components fails trial

The vaccine regimen is based on a canarypox vector-based vaccine called ALVAC-HIV from Sanofi Pasteur and a two-component gp120 protein subunit vaccine supplied by GlaxoSmithKline. ... An HIV vaccine is essential to end the global pandemic, and we hoped

Latest news

  • J&J pledges $500m investment into HIV and tuberculosis R&D J&J pledges $500m investment into HIV and tuberculosis R&D

    Using this investment, J&J has said it will continue to advance various investigational vaccine regimes to help prevent HIV. ... Another experimental study – called HVTN 702 – is testing a vaccine regimen of the ‘Thai combination’ of Sanofi

  • HIV meeting hears progress towards vaccine and cure HIV meeting hears progress towards vaccine and cure

    Another phase 3 HIV vaccine trial is also underway, using a modified version of the ‘Thai combination’ of Sanofi Pasteur’s ALVAC-HIV and GlaxoSmithKline’s bivalent gp120/MF59 that showed ... In 2017, 1.8m people were newly infected with HIV and

  • Efficacy trials get underway for HIV vaccine in South Africa Efficacy trials get underway for HIV vaccine in South Africa

    The vaccine regimen is based on a canarypox vector-based vaccine called ALVAC-HIV from Sanofi Pasteur and a two-component gp120 protein subunit vaccine supplied by GlaxoSmithKline (GSK), and should ... If deployed alongside our current armoury of proven

  • HIV vaccine from J&J starts human trials HIV vaccine from J&J starts human trials

    Our ultimate goal is to develop a vaccine that prevents HIV in the first place.". ... A trial that combined AIDSVAX with a Sanofi Pasteur candidate called ALVAC HIV (vCP1521) showed modest protective efficacy in a Thai trial reported in 2013 but has been

  • Research in HIV therapies Research in HIV therapies

    Results from a proof-of-concept phase III trial (RV144) showed that ALVAC-HIV vCP1521 significantly reduced the rate of HIV infection by 31 per cent, compared with placebo. ... Participants received ALVAC-HIV vCP1521 as the prime and HIV gp120 vaccine

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...